| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency |
|
Medicine details |
|
| Medicine name | setmelanotide (Imcivree®) |
| Formulation | 10 mg/ml solution for injection |
| Reference number | 4297 |
| Indication | Treatment of obesity and the control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above |
| Company | Rhythm Pharmaceuticals |
| BNF chapter | Central nervous system |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/06/2021 |
| NICE guidance | HST21: Setmelanotide for treating obesity caused by LEPR or POMC deficiency |
| Commercial arrangement | PAS |